Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
11 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRIA
WIEN
WIEN
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PATHFINDER: An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis - AT
Institution: Information not provided - AT
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
GERMANIA
Baden-Württemberg
MANNHEIM
CPKC412D2201 - A single arm, phase II, open-label study to determine the efficacy of 100 mg twice daily of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an associated hematological clonal non-mast cell lineage disease - DE
Universitätsmedizin Mannheim
III. Medizinische Klinik
SPAGNA
Castilla - La Mancha
TOLEDO
PATHFINDER: An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis - ES
Hospital Virgen del Valle
Instituto de Estudios de Mastocitosis de Castilla La Mancha
SPAGNA
Castilla - La Mancha
TOLEDO
PIONEER: A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy - ES
Hospital Virgen del Valle
Instituto de Estudios de Mastocitosis de Castilla La Mancha
SPAGNA
Madrid
MADRID
A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap [...] - ES
Hospital Universitario Ramón y Cajal
SPAGNA
Navarra
PAMPLONA
Sperimentazioni cliniche internazionali
SPAGNA
Madrid
COLMENAR VIEJO
APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination)
PharmaMar S.A.
Pharma Mar S.A.
STATI UNITI
Kansas
LAWRENCE
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC.
SVIZZERA
Suisse Alémanique
BASEL